Clinical trials: Prednisone, open to volunteers
Optic Neuritis
Efgartigimod for the Treatment of Acute Optic Neuritis
The goal of this pilot clinical trial is to test efgartigimod alfa against placebo in adults with first-time optic neuritis (optic nerve inflammation).
- Trial name
- PET-AON (NCT06453694)
- Testing
- Efgartigimod Alfa
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Anastasia Vishnevetsky, MD, MPH
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned.
- Trial name
- PREDICT (NCT06632977)
- Testing
- Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging
- Where
- 108 sites in United States
- Volunteers
- 474 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus
- Trial name
- NCT06625671
- Testing
- DB-2304, Prednisone
- Where
- 7 sites in United States, Australia
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- DualityBio Inc.
Immune-mediated Hepatitis, Immune-related Adverse Event
Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy
This phase II study evaluates whether early treatment with mycophenolate mofetil (MMF) plus prednisone improves liver inflammation caused by immune checkpoint inhibitors.
- Trial name
- NCT07663422
- Testing
- Mycophenolate Mofetil plus prednisone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Fox Chase Cancer Center
Acute Lymphoid Leukemia (ALL)
Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL
This single-arm, prospective, multicenter, phase II study will enroll newly diagnosed Philadelphia chromosome-negative (Ph-) acute B-cell lymphoblastic leukemia (B-ALL) patients aged 18-60 years.
- Trial name
- NCT06930105
- Testing
- Blinatumomab plus Reduced-dose Chemotherapy
- Volunteers
- 45 people
- Sponsor
- Xianmin Song, MD
Diffuse Large B Cell Lymphoma (DLBCL)
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).
- Trial name
- GRAIL (NCT06050694)
- Testing
- glofitamab
- Where
- 3 sites in Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Ulcerative Colitis Acute
Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis
The goal of this trial is to create personalized treatments for each patient admitted to the hospital with acute severe ulcerative colitis (ASUC).
- Trial name
- NCT05867329
- Testing
- Cyclosporine Injection (IV), Cyclosporine Oral Product, Upadacitinib Extended Release Oral Tablet
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Berinstein, Jeffrey
ITP - Immune Thrombocytopenia
Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia
This prospective, single-arm, multicenter, exploratory study will enroll 38 adults patients with newly diagnosed primary immune thrombocytopenia (ITP).
- Trial name
- NCT07788456
- Testing
- standard-dose methylprednisolone/prednisone., thrombopoietin receptor agonist(TPO-RA), including but not limited to hetrombopag or eltrombopag., rituximab.
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
FL
Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma
:This is a an open-label, single-arm study to evaluate the efficacy and safety of zanubrutinib and G-CHOP in untreated Intermediate-high risk Follicular Lymphoma patients.
- Trial name
- NCT06474481
- Testing
- Zanubrutinib, Obinutuzumab, Prednisone
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatotoxicity, Idiosyncratic Drug Effect
Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity
This trial´s aim is to assess if oral prednisone (compared to placebo), administered over five weeks is beneficial in terms of decreased total bilirubin (TBL): reduction of the peak of TBL at least 50% at 14 days or reduction in…
- Conditions
- Hepatotoxicity, Idiosyncratic Drug Effect, Prednisone
- Trial name
- DILICORT (NCT06251232)
- Testing
- Prednisone
- Volunteers
- 60 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Diffuse Large B-Cell Lymphoma
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-ZLP as induction therapy in patients with DLBCL.
- Trial name
- NCT06665217
- Testing
- Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy
- Volunteers
- 80 people
- Sponsor
- Navy General Hospital, Beijing
Hepatitis
Severe Hepatitis Intervention With Emapalumab for Liver Disease
The goal of this study is to see whether a medicine called emapalumab, a monoclonal antibody, is safe and works well for patients aged 1 year and older who have indeterminate severe hepatitis with T-cell activation and have not…
- Trial name
- SHIELD (NCT07744919)
- Testing
- Emapalumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Healthcare of Atlanta
Follicular Lymphoma
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
Evaluation of the efficacy and safety of TQB2825 injection compared to immunotherapy in the treatment of recurrent/refractory follicular lymphoma.
- Trial name
- NCT07187960
- Testing
- TQB2825 Injection, Rituximab Injection
- Where
- 28 sites in China
- Volunteers
- 228 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.